-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ty0jLcjg1JYxyVA7D4+AX7v+aqyagrKMlOw6QNEB6nSTNKSQQd4ejwLeh3MPsMFo jHL7AhbiHn6/lGbH+w2Iog== /in/edgar/work/20000718/0000062391-00-000003/0000062391-00-000003.txt : 20000920 0000062391-00-000003.hdr.sgml : 20000920 ACCESSION NUMBER: 0000062391-00-000003 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000718 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TRANSKARYOTIC THERAPIES INC CENTRAL INDEX KEY: 0000885259 STANDARD INDUSTRIAL CLASSIFICATION: [2836 ] IRS NUMBER: 043027191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-47221 FILM NUMBER: 674694 BUSINESS ADDRESS: STREET 1: 195 ALBANY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6173490200 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13D/A 1 0001.txt SCHEDULE 13D/A AMENDMENT #1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment #1 Under the Securities Exchange Act of 1934 TRANSKARYOTIC THERAPIES, INC. ---------------------------- (Name of Issuer) Common Stock par value $.01 per share --------------------------------------------------------------------------- (Title of Class of Securities) 893735 10 0 ----------------- (CUSIP Number) Edward H. Stratemeier, Esq. General Counsel Aventis Pharmaceuticals Route 202-206, P. O. Box 6800 Bridgewater, NJ 08807-0800 - --------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 15, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f), or 13d-1(g), check the following box. [ ] Page 1 of 12 Exhibit Index is at Pages 6 and 7 2 CUSIP No. 893735 10 0 ___________________________________________________________________________ 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ X ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Source of Funds WC ___________________________________________________________________________ 5) Check Box if Disclosure of Legal [ ] Proceedings is Required Pursuant to Items 2(d) or 2(e) ___________________________________________________________________________ 6) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 7) Sole Voting Power 2,187,408 Number of _____________________________________________________________ Shares Beneficially 8) Shared Voting Power 0 Owned by _____________________________________________________________ Each Reporting 9) Sole Dispositive Power 2,187,408 Person With _____________________________________________________________ 10) Shared Dispositive Power 0 ___________________________________________________________________________ 11) Aggregate Amount Beneficially Owned 2,187,408 by Each Reporting Person ___________________________________________________________________________ 12) Check Box If the Aggregate Amount [ ] in Row (11) Excludes Certain Shares ___________________________________________________________________________ 13) Percent of Class Represented 9.6% by Amount in Row (11) ___________________________________________________________________________ 14) Type of Reporting Person CO ___________________________________________________________________________ 3 CUSIP No. 893735 10 0 ___________________________________________________________________________ 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ X ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Source of Funds Not applicable ___________________________________________________________________________ 5) Check Box if Disclosure of Legal [ ] Proceedings is Required Pursuant to Items 2(d) or 2(e) ___________________________________________________________________________ 6) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 7) Sole Voting Power 2,187,408 Number of _______________________________________________________________ Shares Beneficially 8) Shared Voting Power 0 Owned by _______________________________________________________________ Each Reporting 9) Sole Dispositive Power 2,187,408 Person With _______________________________________________________________ 10) Shared Dispositive Power 0 ___________________________________________________________________________ 11) Aggregate Amount Beneficially Owned 2,187,408 by Each Reporting Person ___________________________________________________________________________ 12) Check Box If the Aggregate Amount [ ] in Row (11) Excludes Certain Shares ___________________________________________________________________________ 13) Percent of Class Represented 9.6% by Amount in Row (11) ___________________________________________________________________________ 14) Type of Reporting Person CO ___________________________________________________________________________ 4 CUSIP No. 893735 10 0 This Amendment no. 1 to the Statement on Schedule 13D (the Schedule 13D) with respect to the Common Stock of Transkaryotic Therapies, Inc. (the Issuer), of Aventis Pharmaceuticals Inc., a Delaware corporation (API), and HMR Pharma, Inc., a Delaware corporation (HMR Pharma), is filed solely to incorporate the following exhibits: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Exhibit 99.1 Information concerning directors and executive officers of Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. Exhibit 99.2 Information concerning members of Supervisory Board, Management Board and Executive Committee of Aventis S.A. 5 CUSIP No. 893735 10 0 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: July 18, 2000 By: /s/ Rebecca R. Tilden Rebecca R. Tilden Vice President and Secretary After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: July 18, 2000 By: /s/ Joan A. Hanlon Joan A. Hanlon Vice President and Treasurer 6 CUSIP No. 893735 10 0 EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.1 Information concerning directors and 8 executive officers of API and HMR Pharma. 99.2 Information concerning members of the Supervisory 11 Board, Board of Management and Executive Committee of Aventis S.A. 99.3 Agreement to File Jointly dated December 22, 1999, by and between API and HMR Pharma (incorporated by reference from Schedule 13D dated December 22, 1999). 99.4 Class D Preferred Stock Purchase Agreement, dated May 18, 1994, by and between the Issuer and API (incorporated by reference from Exhibit 10.6 to Amendment No. 5 to the Registration Statement on Form S-1 of the Issuer filed with the Securities and Exchange Commission (the "Commission") on October 15, 1996 (the "Registration Statement")). 99.5 Class E Preferred Stock Purchase Agreement, dated March 1, 1995, by and between the Issuer and API (incorporated by reference from Exhibit 10.7 to Amendment No. 5 to the Registration Statement). 99.6 Class F Preferred Stock Purchase Agreement, dated October 26, 1995, by and among the Issuer and certain Purchasers named therein (incorporated by reference from Exhibit 10.8 to Amendment No. 5 to the Registration Statement). 99.7 Amended and Restated License Agreement, dated March 1, 1995, by and between API and the Issuer (incorporated by reference from Exhibit 10.33 to Amendment No. 5 to the Registration Statement). 99.8 License Agreement, dated March 1, 1995, by and between API and the Issuer (incorporated by reference from Exhibit 10.34 to Amendment No. 5 to the Registration Statement). 99.9 Amended and Restated Registration Rights Agreement, dated November 3, 1993 and amended on May 13, 1994, March 1, 1995, October 26, 1995, July 10, 1996 and August 7, 1996, by and among the Issuer and certain holders of the Issuer's Preferred Stock named therein (incorporated by reference from Exhibit 10.11 7 CUSIP No. 893735 10 0 to Amendment No. 5 to the Registration Statement). 99.10 Fifth Amendment to Registration Rights Agreement dated October 1, 1996 by and among the Issuer and certain holders of the Issuer's Preferred Stock named therein (incorporated by reference from Exhibit 10.36 to Amendment No. 5 to the Registration Statement). 8 CUSIP No. 893735 10 0 Exhibit 99.1 Directors and Officers of Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. The following sets forth the name, title, business address, and present principal occupation of each of the directors and executive officers of API as of June 5, 2000. All are citizens of the United States unless otherwise indicated in parentheses under his or her name. AVENTIS PHARMACEUTICALS INC.
>C> Name Title Address Daniel Camus Chief Financial Officer Aventis Pharma AG (Germany) of Aventis Pharma AG 65926 Frankfurt Main and Director of API Germany Frank L. Douglas, Ph.D., M.D. Head of Research and Aventis Pharma AG Development of Aventis 65926 Frankfurt Main Pharma AG and Director Germany of API Richard J. Markham Chief Executive Officer Route 202-206 of Aventis Pharma AG Bridgewater, NJ 08807-0800 and Director of API Thierry Soursac, M.D., Ph.D. Head of Commercial Route 202-206 Operations for Aventis Bridgewater, NJ 08807-0800 Pharma AG and Director of API Gerald P. Belle President and Chief Executive Route 202-206 Officer and Director of API Bridgewater, NJ 08807-0800 Harold F. Boardman Senior Vice President, Legal Route 202-206 Bridgewater, NJ 08807-0800 Susan Ketterman Vice President, Head of NA Route 202-206 Human Resources Bridgewater, NJ 08807-0800 John R. Leone Sr. Vice President, US Route 202-206 Commercial Operations Bridgewater, NJ 08807-0800 Jurgen Lasowski Vice President, Business Route 202-206 Development and Strategy, Bridgewater, NJ 08807-0800 NA Philippe M. Maitre Vice President, Head of NA Route 202-206 (France) Finance and Information Systems Bridgewater, NJ 08807-0800 and Chief Financial Officer Daniel G. Maher Vice President, Head of NA 10236 Marion Park Drive Industrial Operations Kansas City, MO 64137 Francois Nader, MD Vice President, Head of NA Route 202-206 Medical Affairs/Regulatory Bridgewater, NJ 08807-0800 9 CUSIP No. 893735 10 0 Charles F. Rouse, III Vice President, Head of NA Route 202-206 Communications and Bridgewater, NJ 08807-0800 Community Affairs Mark R. Shaw Vice President, Head of NA Route 202-206 Administrative Services Bridgewater, NJ 08807-0800 Edward H. Stratemeier Vice President, Head of NA Route 202-206 Legal, Government Affairs Bridgewater, NJ 08807-0800 and Policy Robert J. Carmody Vice President, North America Route 202-206 Tax Bridgewater, NJ 08807-0800 Gerald Dahling Senior Vice President, 2, Avenue Pont Pasteur Global Patents Lyon, France 69007 Charles D. Dalton Vice President and Assistant Route 202-206 Secretary Bridgewater, NJ 08807-0800 Tim C. Gau Senior Vice President, Route 202-206 Head of Global Drug Product Bridgewater, NJ 08807-0800 Realization, Drug Regulatory Affairs & Drug Surveilance Thomas Hofstaetter Senior Vice President, Route 202-206 Corporate Development Bridgewater, NJ 08807-0800 Claude Ourceyre Vice President, Corporate Route 202-206 Human Resources - Bridgewater, NJ 08807-0800 Bridgewater Center Kirk Schueler Senior Vice President, Global Route 202-206 Marketing Bridgewater, NJ 08807-0800 Errol de Souza Vice President, Head of Route 202-206 DI&A U.S. Bridgewater, NJ 08807-0800 Scott F. Stevens Vice President, Global Tax Route 202-206 Bridgewater, NJ 08807-0800 Rebecca R. Tilden Vice President and Secretary 10236 Marion Park Drive Kansas City, MO 64137 Michael A. Yeomans Vice President, Licensing & Route 202-206 Alliances Bridgewater, NJ 08807-0800 Terry G. King Treasurer Route 202-206 Bridgewater, NJ 08807-0800 E. Todd Johnson Assistant Treasurer 10236 Marion Park Drive Kansas City, MO 64137 Owen K. Ball, Jr. Assistant Secretary Route 202-206 Bridgewater, NJ 08807-0800 Christian Gelain Assistant Secretary 25, Quai Paul Doumer (France) Courbevoie, France 92408 Ross J. Oehler Assistant Secretary Route 202-206 Bridgewater, NJ 08807-0800 Robert J. Werner Assistant Secretary Route 202-206 Bridgewater, NJ 08807-0800
10 CUSIP No. 893735 10 0
HMR PHARMA, INC. >C> Directors: Gerald P. Belle Chairman Route 202-206 Bridgewater, NJ 08807-0800 Philippe M. Maitre Director Route 202-206 (France) Bridgewater, NJ 08807-0800 Edward H. Stratemeier Director Route 202-206 Bridgewater, NJ 08807-0800 Officers: Phillip R. Ridolfi President 3711 Kennett Pike, Suite 200 Greenville, DE 19807 Joan A. Hanlon Vice President & Treasurer 3711 Kennett Pike, Suite 200 Greenville, DE 19807 Andrea Q. Ryan Secretary 3711 Kennett Pike, Suite 200 Greenville, DE 19807
11 CUSIP No. 893735 10 0 Exhibit 99.2 Certain Information Relating to Directors and Executive Officers Supervisory Board, Board of Management and Executive Committee of Aventis SA
Name and Business Address Principal Present Occupation SUPERVISORY BOARD Marc Vienot Chairman of the Supervisory Board of Aventis (France) Dr. Martin Fruhauf Vice-Chairman of the Supervisory Board of Aventis (Germany) Jean-Marc Bruel Member of the Supervisory Board of Aventis (France) Serge Kampf Member of the Supervisory Board of Aventis (France) Prof. Dr. Drs. h. c. Hubert Markl Member of the Supervisory Board of Aventis (Germany) Dr. Gunter Metz Member of the Supervisory Board of Aventis (Germany) Didier Pineau-Valencienne Member of the Supervisory Board of Aventis (France) Seham Razzouqi Member of the Supervisory Board of Aventis (Kuwait) Michel Renault Member of the Supervisory Board of Aventis (France) Dr. Hans-Jurgen Schinzler Member of the Supervisory Board of Aventis (Germany) BOARD OF MANAGEMENT Jurgen Dormann Chairman of the Board of Management of Aventis (Germany) Jean-Rene Fourtou Vice-Chairman of the Board of Management of Aventis (France) 12 CUSIP No. 893735 10 0 Igor Landau Member of the Board of Management of Aventis (France) Horst Waesche Member of the Board of Management of Aventis (Germany) EXECUTIVE COMMITTEE Jurgen Dormann Chairman of the Board of Management of Aventis (Germany) Jean- Rene Fourtou Vice-Chairman of the Board of Management of Aventis (France) Alain Godard Chief Executive Officer of Aventis Agriculture (France) Igor Landau Member of the Board of Management of Aventis (France) Patrick Langlois Group Executive Vice President - Chief Financial (France) Officer Richard J. Markham Chief Executive Officer of Aventis Pharma (United States) Rene Penisson Group Executive Vice President - Human Resources ( France) Horst Waesche Member of the Board of Management of Aventis (Germany)
-----END PRIVACY-ENHANCED MESSAGE-----